BWI-CTU Researchers Elected to ACTG Network Committees

Published Date:

11/30/2016

November 29, 2016—The ACTG Network announced today the results of elections for the network's laboratory, leadership, science, and resource committees. Congratulations to the following BWI-CTU researchers, who were elected to serve for the term of December 1, 2016 – November 30, 2017:

  • Christine Durand, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
     
  • David Hardy, Whitman-Walker Clincial Trials Site (Washington)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Ya-Chi Ho, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, HIV Reservoirs & Viral Eradication Transformative Science Group.  
      
  • Charles Flexner, Johns Hopkins Clincial Trials Site (Baltimore)
    Non-voting Member, Antiretroviral Therapy Strategies Subcommittee.  
        
  • Vidya Mave, Byramjee Jeejeebhoy Clincial Trials Site (India)
    Investigator, Tuberculosis Transformative Science Group.  
       
  • Eric Nuermberger, Johns Hopkins Clincial Trials Site (Baltimore)
    Investigator, Tuberculosis Transformative Science Group.  
        
  • Ilene Wiggins, Johns Hopkins Clincial Trials Site (Baltimore)
    Chair, Site Management & Clinical Care Committee

Clinical Trials

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More